Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertisements.

• Adaptogenics is pursuing three complementary opportunities across pharmaceutical-quality peptide supply, proprietary therapeutics and next-generation delivery technologies.
• Its planned supply network could generate commercial revenue while supporting therapeutic development through external manufacturing and laboratory partners.
• The company is targeting metabolic health, muscle preservation, mitochondrial function, recovery and healthy ageing through proprietary peptide and small-molecule therapeutics.
• CEO Dr. J. David Warren brings a scientific record that includes 17 issued patents, while President Antoun Nabhan brings experience spanning more than $2 billion in healthcare transactions and two Nasdaq IPO processes.
• Adaptogenics is evaluating non-injectable and targeted local delivery technologies that could improve peptide utility, generate intellectual property and expand commercial applications.

Adaptogenics (CSE: ADPT) is building a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies.

As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply.

The company’s strategy combines experienced pharmaceutical leadership, scientific innovation and a capital-efficient business model designed to create both near-term commercial opportunities and long-term value through proprietary therapeutic assets.

Three Opportunities Driving Adaptogenics’ Strategy

1. Pharmaceutical-Quality Peptide Supply

The growing interest in peptide-based healthcare is creating opportunities for reliable manufacturing, independent quality verification and transparent supply chains.

Adaptogenics is working toward establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, supported by qualified manufacturing partners, analytical laboratories and documented chain-of-custody procedures.

The company’s objective is to develop a trusted supply model that can serve appropriate research, pharmaceutical and healthcare customers, subject to applicable regulatory requirements.

Rather than investing heavily in manufacturing facilities, Adaptogenics intends to leverage qualified external partners while building its own standards, development capabilities and commercial relationships.

This strategy could establish a foundation for future commercial revenue while supporting the company’s proprietary therapeutic development programs.

2. Proprietary Peptide and Small Molecule Therapeutics

Adaptogenics is pursuing the development of proprietary peptide and small molecule therapeutics targeting some of the most important challenges in modern healthcare.

Key areas of scientific and commercial interest include:

• Metabolic Health: Exploring therapeutic approaches relevant to obesity, metabolic dysfunction and the growing use of GLP-1 treatments.
• Muscle Preservation and Physical Function: Pursuing opportunities to address muscle loss, reduced strength and functional decline associated with ageing and metabolic conditions.
• Mitochondrial Health: Investigating peptide approaches targeting cellular energy and mitochondrial function.
• Recovery and Tissue Repair: Evaluating therapeutic candidates and delivery strategies that could address limitations in existing approaches to healing and recovery.
• Healthy Ageing: Exploring opportunities to preserve physical function and improve health outcomes as populations age.

The company’s objective is to generate differentiated intellectual property, advance promising candidates through meaningful scientific milestones and establish opportunities for future pharmaceutical partnerships, licensing and commercialization.

3. Next-Generation Peptide Delivery Technologies

Many peptide therapeutics face challenges related to administration, stability and absorption.

Adaptogenics is evaluating delivery technologies designed to address these limitations, including non-injectable approaches and targeted local delivery systems.

Successful development could improve the potential utility of selected peptide therapeutics, create additional intellectual property and expand their commercial applications.

The company’s approach is to select delivery technologies based on measurable performance advantages rather than pursuing a single delivery method across every molecule.

Leadership Built for Execution

Dr. J. David Warren, PhD – Chief Executive Officer

Dr. Warren is an accomplished medicinal and peptide chemist with extensive experience in therapeutic research and development.

His scientific background includes:

• 17 issued U.S. and international patents.
• More than 53 scientific publications and book chapters.
• Research experience at Weill Cornell Medicine.
• Foundational research involving the mitochondrial peptide SS-31 and its interaction with cardiolipin.

SS-31 was subsequently developed as elamipretide, marketed as Forzinity, which received FDA accelerated approval in 2025 for Barth syndrome. The product was developed by another company and is not an Adaptogenics asset.

Dr. Warren’s expertise in peptide chemistry, molecular design and drug development provides scientific leadership for Adaptogenics’ therapeutic development strategy.

Antoun Nabhan – President

Mr. Nabhan brings extensive healthcare transaction, financing and corporate development experience to Adaptogenics.

His background includes:

• More than US$2 billion in healthcare transactions.
• Experience supporting two Nasdaq IPO processes.
• Senior leadership and corporate development experience across pharmaceutical and biotechnology companies.
• Experience identifying, financing and advancing healthcare opportunities.

His expertise supports the company’s strategic partnerships, capital formation and long-term corporate development objectives.

Building Momentum

Adaptogenics is entering an important phase of its corporate development, with a strategy focused on advancing proprietary therapeutics, establishing pharmaceutical-quality supply capabilities and building a foundation for commercial growth.

Key priorities and anticipated milestones include:

• U.S. Pharmaceutical-Quality Supply: Establishing a U.S.-based GMP manufacturing and independently verified peptide supply network, creating a foundation for potential commercial opportunities and strategic healthcare partnerships.
• Proprietary Therapeutic Pipeline: Advancing peptide and small molecule development programs targeting high-value opportunities in metabolic health, muscle preservation, recovery and healthy ageing.
• Next-Generation Delivery: Progressing formulation and delivery research aimed at overcoming limitations in peptide administration, stability and bioavailability.
• Scientific Validation and Intellectual Property: Generating experimental data, advancing proprietary molecular designs and identifying opportunities to strengthen patent protection.
• Commercial Expansion: Developing relationships with healthcare providers, pharmacies and strategic distribution partners to identify compliant routes to market.
• Strategic Growth and Capital Markets: Building institutional relationships and positioning the company for its next phase of development and potential growth financing.

Together, these initiatives are intended to position Adaptogenics to advance from foundational research and infrastructure development toward proprietary therapeutic assets, potential commercial opportunities and measurable value creation.

The Long-Term Vision

Adaptogenics aims to build a substantial healthcare company operating across complementary segments of the peptide industry.

The company’s long-term vision combines:

• Commercial Opportunity: Establishing pharmaceutical-quality peptide supply capabilities and healthcare distribution relationships that could support future revenue generation.
• Scientific Innovation: Developing proprietary peptide and small molecule therapeutics addressing significant healthcare needs.
• Intellectual Property: Creating and securing differentiated molecular, formulation and delivery technologies with potential commercial value.
• Strategic Partnerships: Working with pharmaceutical companies, research institutions, qualified manufacturers and healthcare organizations to accelerate development and expand market opportunities.
• Scalable Growth: Building a capital-efficient business that can expand its therapeutic portfolio and commercial capabilities without requiring ownership of every manufacturing or research facility.

Adaptogenics believes the convergence of peptide innovation, advances in metabolic medicine and growing global demand for healthier ageing creates an opportunity for companies capable of combining scientific expertise with pharmaceutical-quality development and commercial execution.

The company’s ambition is to participate in this evolving healthcare landscape by building proprietary assets, advancing innovative therapies and establishing the infrastructure to support long-term growth.

NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN